Last reviewed · How we verify
Synflorix™ vaccine
Synflorix is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 10 serotypes of Streptococcus pneumoniae.
Synflorix is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 10 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal otitis media in infants and children, Prevention of pneumococcal pneumonia in infants and children.
At a glance
| Generic name | Synflorix™ vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains polysaccharide antigens from 10 pneumococcal serotypes conjugated to a protein carrier (diphtheria toxoid), which enhances immunogenicity and T-cell dependent responses. This conjugation allows the vaccine to elicit both humoral and cellular immune responses, providing protection against invasive pneumococcal disease, pneumonia, and otitis media caused by these serotypes.
Approved indications
- Prevention of invasive pneumococcal disease in infants and children
- Prevention of pneumococcal otitis media in infants and children
- Prevention of pneumococcal pneumonia in infants and children
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™ (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers (PHASE1)
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (PHASE2)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age (PHASE2)
- Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam (PHASE3)
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |